Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

600.66 -14.12 (-2.30%)
Official Closing Price Updated: 4:15 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN): Grabar Law Office is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Molina Healthcare, Inc. (NYSE: MOH); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Grabar Law Office is Investigating Claims on
From Grabar Law Office
Via GlobeNewswire
News headline image
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
Hikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world’s largest pre-college STEM competition 
From Society For Science
Via GlobeNewswire
News headline image
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Reports First Quarter 2026 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Telix and Regeneron Announce Strategic Radiopharma Collaboration
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Regeneron and Telix Announce Strategic Radiopharma Collaboration
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Investor Conference Presentation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
From Society For Science
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.